Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?

被引：6

作者：

Brockelmann, Paul J. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Fac Med, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany

[2] Univ Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Univ Hosp Cologne, Kerpener Str 62, D-50937 Cologne, Germany

[3] German Hodgkin Study Grp GHSG, Cologne, Germany

[4] Oncol Aachen Bonn Cologne Dusseldorf MSSO ABCD, Mildred Scheel Sch, Cologne, Germany

[5] Max Planck Inst Biol Ageing, Cologne, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 196卷 / 01期

关键词：

PHASE-II; TRANSPLANTATION; REVEALS; ARM;

D O I：

10.1111/bjh.17891

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10 / 12

页数：3

共 19 条

[11] Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma? [J].

Crump, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (02) :97-+

[12]

D?rr, 2021, EXHAUSTIVE CIRCULATI, DOI [10.1101/2021.03.16.21253679, DOI 10.1101/2021.03.16.21253679]

[13] Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents [J].

Galluzzi, Lorenzo ;

Buque, Aitziber ;

Kepp, Oliver ;

Zitvogel, Laurence ;

Kroemer, Guido .

CANCER CELL, 2015, 28 (06) :690-714

[14] Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma [J].

Moskowitz, Alison J. ;

Shah, Gunjan ;

Schoeder, Heiko ;

Ganesan, Nivetha ;

Drill, Esther ;

Hancock, Helen ;

Davey, Theresa ;

Perez, Leslie ;

Ryu, Sunyoung ;

Sohail, Samia ;

Santarosa, Alayna ;

Galasso, Natasha ;

Neuman, Rachel ;

Liotta, Brielle ;

Blouin, William ;

Kumar, Anita ;

Lahoud, Oscar ;

Batlevi, Connie L. ;

Hamlin, Paul ;

Straus, David J. ;

Rodriguez-Rivera, Ildefonso ;

Owens, Colette ;

Caron, Philip ;

Intlekofer, Andrew M. ;

Hamilton, Audrey ;

Horwitz, Steven M. ;

Falchi, Lorenzo ;

Joffe, Erel ;

Johnson, William ;

Lee, Christina ;

Palomba, M. Lia ;

Noy, Ariela ;

Matasar, Matthew J. ;

Pongas, Georgios ;

Salles, Gilles ;

Vardhana, Santosha ;

Sanin, Beatriz Wills ;

von Keudell, Gottfried ;

Yahalom, Joachim ;

Dogan, Ahmet ;

Zelenetz, Andrew D. ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28) :3109-+

[15] Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma [J].

Nie, Jing ;

Wang, Chunmeng ;

Liu, Yang ;

Yang, Qingming ;

Mei, Qian ;

Dong, Liang ;

Li, Xiang ;

Liu, Jiejie ;

Ku, Wenjing ;

Zhang, Yan ;

Chen, Meixia ;

An, Xiaojing ;

Shi, Lu ;

Brock, Malcolm, V ;

Bai, Jie ;

Han, Weidong .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) :1479-+

[16] Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma [J].

Ramos, Carlos A. ;

Grover, Natalie S. ;

Beaven, Anne W. ;

Lulla, Premal D. ;

Wu, Meng-Fen ;

Ivanova, Anastasia ;

Wang, Tao ;

Shea, Thomas C. ;

Rooney, Cliona M. ;

Dittus, Christopher ;

Park, Steven I. ;

Gee, Adrian P. ;

Eldridge, Paul W. ;

McKay, Kathryn L. ;

Mehta, Birju ;

Cheng, Catherine J. ;

Buchanan, Faith B. ;

Grilley, Bambi J. ;

Morrison, Kaitlin ;

Brenner, Malcolm K. ;

Serody, Jonathan S. ;

Dotti, Gianpietro ;

Heslop, Helen E. ;

Savoldo, Barbara .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3794-+

[17] Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 [J].

Reinke, Sarah ;

Broeckelmann, Paul J. ;

Iaccarino, Ingram ;

Garcia-Marquez, Maria ;

Borchmann, Sven ;

Jochims, Franziska ;

Kotrova, Michaela ;

Pal, Karol ;

Brueggemann, Monika ;

Hartmann, Elena ;

Sasse, Stephanie ;

Kobe, Carsten ;

Mathas, Stephan ;

Soekler, Martin ;

Keller, Ulrich ;

Bormann, Matthias ;

Zimmermann, Andreas ;

Richter, Julia ;

Fuchs, Michael ;

von Tresckow, Bastian ;

Borchmann, Peter ;

Schloesser, Hans ;

von Bergwelt-Baildon, Michael ;

Rosenwald, Andreas ;

Engert, Andreas ;

Klapper, Wolfram .

BLOOD, 2020, 136 (25) :2851-2863

[18] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study [J].

Song, Yuqin ;

Gao, Quanli ;

Zhang, Huilai ;

Fan, Lei ;

Zhou, Jianfeng ;

Zou, Dehui ;

Li, Wei ;

Yang, Haiyan ;

Liu, Ting ;

Wang, Quanshun ;

Lv, Fangfang ;

Guo, Haiyi ;

Yang, Liudi ;

Elstrom, Rebecca ;

Huang, Jane ;

Novotny, William ;

Wei, Vivian ;

Zhu, Jun .

LEUKEMIA, 2020, 34 (02) :533-542

[19] Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma [J].

Zhang, Yu-Chen ;

Wang, Jin-Ni ;

Ma, Shu-Yun ;

Cai, Jun ;

Su, Ning ;

Huang, Hui-Qiang ;

Li, Zhi-Ming ;

Xia, Zhong-Jun ;

Huang, He ;

Liu, Pan-Pan ;

Xia, Yi ;

Cai, Qing-Qing .

BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) :127-135

← 1 2 →